SOVRENINS
Investo's verdict, shared with you
No fair value published
The derivation ran and was refused by our own plausibility checks. We publish no number rather than a plausible-looking one.
Why · 2 checks
Our valuation methods disagree
The earnings-based and book-based readings of this company differ by more than 2.5×. That spread is real information, but averaging it would manufacture a number no method actually produced.
The derivation failed our plausibility check
The computed value landed outside the 0.4×–2.5× band that real price targets occupy. A result that far from the traded price means one of our inputs is wrong, not that the market is wrong by that much — so we publish nothing rather than clamp it into range.
What we would need
- Earnings and book value drawn from the same set of accounts, so the two legs can be reconciled.
- A per-share input (earnings or book value) that reconciles to the latest audited totals.
Show what the engine computed
Rejected figure · ₦0.74 — floor — raw base ₦0.74 is 0.39x price. This figure is shown only to document what was refused; it is not an estimate and no upside is computed from it.
Method spread · 2.75× between the highest and lowest valuation leg.
Methods disagree · The valuation legs disagree by 2.75x (Blended P/E band ₦0.45 vs Blended P/B band ₦1.1 vs Justified P/B ₦0.4). No point estimate is defensible until the inputs are reconciled.
Failed plausibility rail · Fair value hit our plausibility bounds: floor — raw base ₦0.74 is 0.39x price. The published base is the rail, not a derivation.
Sovereign Trust Insurance trades at ₦1.90, implying a P/E of ~32x on ₦0.06 EPS and a P/B of ~1.91x on ₦0.99 BVPS — both materially above peer-median multiples of 7.63x P/E and 1.11x P/B for Nigerian insurance peers. Underlying fundamentals are deteriorating sharply: Q2 2026 half-year results show a 37% YoY decline in insurance revenue, a 59% drop in insurance service result, and a 47% decline in PAT, while ROE of ~6% sits well below an estimated cost of equity of ~18%, destroying economic value. A pending recapitalisation adds further dilution and execution risk to an already expensive, quality-challenged name.
Verdict published 2026-08-12 · fundamentals through FY2025 · reviewed as the data changes
Verdict moderated to Watch — Avoid was refused
Fair value hit our plausibility bounds, so there is no defensible valuation behind an extreme call.
Source: NGX live market data · Investo intelligence. Educational only — not financial advice.